

**CARIS & COMPANY**  
**CO-MANAGES 3 MILLION SHARE INITIAL PUBLIC**  
**OFFERING FOR RESPONSE GENETICS**  
**(NASDAQ:RGDX)**

**Del Mar, CA-** June 5, 2007- Caris & Company is pleased to announce the pricing of an initial public offering for Response Genetics, Inc. (NASDAQ: RGDX). Caris served as a co-manager in the transaction. The offering consisted of 3,000,000 shares of common stock at a price of \$7.00 per share and trades on the Nasdaq Capital Market under the symbol "RGDX". Response Genetics has granted the underwriters a 45 day over-allotment option to purchase an additional 450,000 shares of common stock.

**About Response Genetics, Inc.**

Response Genetics, Inc. ("RGI") (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California.

**About Caris & Company**

Established in 2002, Caris & Company is a full service investment bank that services Wall Streets institutional investment community by providing differentiated, collaborative, alpha generating ideas. Headquartered in Del Mar, CA, Caris & Company has offices in New York, San Francisco, and Boston. The firms' research product includes coverage in the following areas: Biotechnology, Medical Devices, Medical Diagnostics, Healthcare IT, Semiconductors, Semi-Cap Equipment, Storage, Internet Services, Refining, Coal, Home Furnishings, Specialty Retail, Consumer Electronics, and Action Sports Retailers.

Media Contact:

Judy Jeub

[jjeub@cariscompany.com](mailto:jjeub@cariscompany.com)

858-704-0311